Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + trastuzumab for advanced extramammary Paget's disease (EMPD-HER2DOC)
jRCTs031180073Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and trastuzumab in extramammary Paget disease (EMPD), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Objective response rate after three dosing cycles. Started Apr 2017; status: completed.
02
Drugs
docetaxeltrastuzumab
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on jRCTs031180073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180073.